Kenya - English - Pharmacy and Poisons Board

bilthoven biologicals b.v antonie van leeuwenhoeklaan 9-13, bilthoven, 3721 - inactivated poliomyelitis virus type 1… - suspension for injection - inactivated poliomyelitis virus type 1 -40… - viral vaccines: poliomyelitis vaccines

Canada - English - Health Canada

sanofi pasteur limited - inactivated poliomyelitis vaccine (d.c.o.) type 2 mef1; inactivated poliomyelitis vaccine (d.c.o.) type 3 saukett; inactivated poliomyelitis vaccine (d.c.o.) type 1 mahoney - solution - 8unit; 32unit; 40unit - inactivated poliomyelitis vaccine (d.c.o.) type 2 mef1 8unit; inactivated poliomyelitis vaccine (d.c.o.) type 3 saukett 32unit; inactivated poliomyelitis vaccine (d.c.o.) type 1 mahoney 40unit - vaccines

Namibia - English - Namibia Medicines Regulatory Council

bilhoven biological - poliomyelitis vaccine - vaccine - one human dose of 0.5 ml ipv contains - inacticated poliomyelitis virus type 1-40 d-antigen units; inactivated poliomyelitis vir

Zimbabwe - English - Medicines Control Authority

bilthoven biologicals b.v, - poliomyelitis (types 1,2,3; inactivated) - vaccine - 40; 8; 32 d antigen

Zimbabwe - English - Medicines Control Authority

bilthoven biologicals b.v, - poliomyelitis (types 1,2,3; inactivated) - vaccine - 40; 8; 32 d antigen

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi pasteur msd ltd - polio virus type 1 inactivated, polio virus type 2 inactivated, polio virus type 3 inactivated - suspension for injection - %v/v - poliomyelitis vaccines

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi pasteur - polio virus type 1 inactivated, polio virus type 2 inactivated, polio virus type 3 inactivated - suspension for injection - %v/v - poliomyelitis vaccines

Philippines - English - FDA (Food And Drug Administration)

n/a; importer: sanofi pasteur, inc.; distributor: n/a - inactivated poliomyelitis vaccine (type 1,2 and 3) - suspension for injection (im/sc) - formulation: one dose (0.5 ml) contains: poliovirus type 1, mahoney strain (inactivated)-40 d-antigen units poliovirus type 2, mff-i strain (inactivated)- 8 d-antigen units poliovirus type 3, saukett strain (inactivated) - 32 d-antigen units

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - poliovirus, quantity: 17 dagu; poliovirus, quantity: 20 dagu; poliovirus, quantity: 5 dagu - injection, suspension - excipient ingredients: sodium hydroxide; hydrochloric acid; formaldehyde solution; phenoxyethanol; glucose monohydrate; purified water; polysorbate 80; ascorbic acid; sodium chloride; aminobenzoic acid; adenosine phosphate; dl-alpha-tocopheryl phosphate disodium; magnesium sulfate; monobasic potassium phosphate; deoxyribose; calcium chloride dihydrate; iron trinitrate; potassium chloride; magnesium sulfate heptahydrate; potassium nitrate; sodium selenite; monobasic sodium phosphate; dibasic sodium phosphate heptahydrate; adenine sulfate; adenosine triphosphate disodium; cholesterol; glutathione; guanine hydrochloride; hypoxanthine; phenolsulfonphthalein; ribose; sodium acetate; thymine; uracil; xanthine; sodium pyruvate; dl-alanine; arginine hydrochloride; dl-aspartic acid; cysteine hydrochloride; cystine dihydrochloride; dl-glutamic acid; glutamine; glycine; histidine hydrochloride; hydroxyproline; isoleucine; asparagine; dl-leucine; lysine hydrochloride; dl-methionine; dl-phenylalanine; proline; dl-serine; - ipol is indicated for active immunisation of infants, children and adults for the prevention of poliomyelitis. ipol should be offered to patients who have refused opv or in whom opv is contraindicated. ipol is also indicated for: 1) the primary vaccination of immunocompromised individuals of all ages, and household contacts of such individuals (when vaccination is indicated); (2) unvaccinated or inadequately vaccinated(*) adults, particularly if at increased risk of exposure to live polio virus, including: - travellers to areas or countries where poliomyelitis is epidemic or endemic: - laboratory workers handling specimens which may contain polio virus; - health care workers in close contact with patients who may be excreting polioviruses. (*) such as those who may not have completed a primary series of vaccination or not received a booster dose since infancy. idications as at 9 june 2003: ipol is indicated for active immunisation of infants, children and adults for the prevention of poliomyelitis. recommen

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - poliomyelitis virus type 1; poliomyelitis virus type 1; poliomyelitis virus type 3 - suspension - poliomyelitis virus type 3 nlt 10^6.0 ccid50; poliomyelitis virus type 1 nlt 10^5.8 ccid50; poliomyelitis virus type 1 nlt 10^6.0 ccid50 - poliomyelitis oral, monovalent live attenuated - active immunisation against poliomyelitis infection caused by types 1 and 3 poliomyelitis viruses at any age after receiving at least one dose of ipv.